MA52507A - Capsules molles de calcifédiol - Google Patents

Capsules molles de calcifédiol

Info

Publication number
MA52507A
MA52507A MA052507A MA52507A MA52507A MA 52507 A MA52507 A MA 52507A MA 052507 A MA052507 A MA 052507A MA 52507 A MA52507 A MA 52507A MA 52507 A MA52507 A MA 52507A
Authority
MA
Morocco
Prior art keywords
soft capsules
calcifediol
calcifediol soft
capsules
soft
Prior art date
Application number
MA052507A
Other languages
English (en)
Inventor
Arenal Barrios Pepa Del
Herrero Gonzalo Hernández
Azpitarte Ignacio Ortega
Negre Josep María Suñé
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA52507(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MA52507A publication Critical patent/MA52507A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Lubricants (AREA)
  • Carbon And Carbon Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Paints Or Removers (AREA)
MA052507A 2015-02-06 2016-02-05 Capsules molles de calcifédiol MA52507A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15382042.8A EP3053598A1 (fr) 2015-02-06 2015-02-06 Capsules molles de calcifédiol

Publications (1)

Publication Number Publication Date
MA52507A true MA52507A (fr) 2021-03-10

Family

ID=52462260

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41058A MA41058B1 (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol
MA052507A MA52507A (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA41058A MA41058B1 (fr) 2015-02-06 2016-02-05 Capsules molles de calcifédiol

Country Status (30)

Country Link
US (1) US10525018B2 (fr)
EP (3) EP3053598A1 (fr)
JP (2) JP6427270B2 (fr)
KR (1) KR101971384B1 (fr)
CN (2) CN106999441B (fr)
AU (1) AU2016214336B2 (fr)
BR (1) BR112017010657B1 (fr)
CA (1) CA2967170C (fr)
CL (1) CL2017001335A1 (fr)
CO (1) CO2017004545A2 (fr)
CY (1) CY1122976T1 (fr)
DK (2) DK3204047T3 (fr)
EA (1) EA034821B1 (fr)
ES (2) ES2738642T3 (fr)
HR (1) HRP20200859T1 (fr)
HU (1) HUE050133T2 (fr)
LT (1) LT3204047T (fr)
MA (2) MA41058B1 (fr)
MD (1) MD3204047T2 (fr)
ME (1) ME03739B (fr)
MX (1) MX367999B (fr)
MY (1) MY189432A (fr)
PE (1) PE20170911A1 (fr)
PH (1) PH12017501350A1 (fr)
PL (1) PL3204047T3 (fr)
PT (1) PT3204047T (fr)
RS (2) RS64166B1 (fr)
SI (1) SI3204047T1 (fr)
WO (1) WO2016124724A1 (fr)
ZA (1) ZA201703444B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol
CN108542908A (zh) * 2018-06-08 2018-09-18 唐飞 25-羟基维生素d3在制备治疗或预防肝性骨病药物中的应用
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021011538A1 (fr) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Formes galéniques capsules, leurs procédés de préparation et leurs procédés d'utilisation
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
US20240000808A1 (en) * 2020-11-16 2024-01-04 Orcosa Inc. Improved use of cannabinoids in the treatment of alzheimer's disease
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022224001A1 (fr) 2021-04-22 2022-10-27 Faes Farma, S.A. Schéma posologique universel de 25-hydroxy vitamine d3
CN114159402A (zh) * 2021-12-21 2022-03-11 湖州展望天明药业有限公司 一种不透明植物胶囊及其制备方法
CN114712505B (zh) * 2022-03-10 2023-09-05 南方医科大学南方医院 维生素d受体激动剂在制备预防和/或治疗炎症性骨丢失的药物中的应用
WO2024129811A1 (fr) * 2022-12-14 2024-06-20 R.P. Scherer Technologies, Llc Capsules de gel mou et procédé de préparation des capsules de gel mou
CN116270520A (zh) * 2023-03-03 2023-06-23 正大制药（青岛）有限公司 一种维生素d胶囊型滴剂及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4532126A (en) 1982-05-07 1985-07-30 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
GB8305693D0 (en) 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS6335411A (ja) 1986-07-29 1988-02-16 Tonen Sekiyukagaku Kk 高純度合成石英の製造方法
US4997824A (en) 1987-07-22 1991-03-05 Teva Pharmaceutical Industries Ltd. Combination of cholecalciferol derivatives for the treatment of renal bone disease
JPH04288016A (ja) 1991-03-14 1992-10-13 Tokai Capsule Kk 活性型ビタミンｄ３類軟カプセル剤の製造方法
JPH054925A (ja) 1991-06-27 1993-01-14 Teikoku Chem Ind Corp Ltd アルフアカルシドール軟カプセル製剤
JP2684587B2 (ja) 1993-06-21 1997-12-03 呉羽化学工業株式会社 腎性骨異栄養症における骨量減少抑制剤
US6340473B1 (en) 1999-07-07 2002-01-22 R.P. Scherer Technologies, Inc. Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
CN1179725C (zh) * 1999-08-31 2004-12-15 中外制药株式会社 软胶囊剂
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
BR0214679A (pt) 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
AU2003230191A1 (en) 2002-02-20 2003-09-09 Strides Arcolab Limited Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
WO2003086415A1 (fr) 2002-04-05 2003-10-23 Merck & Co., Inc. Procede d'inhibition de resorption osseuse a l'aide d'une formulation a base d'alendronate et de vitamine d
US7438903B2 (en) 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US7332482B2 (en) 2003-09-24 2008-02-19 Bioxell S.P.A. Method for treating benign prostatic hyperplasia
US20050142185A1 (en) 2003-12-29 2005-06-30 Beleno Alfredo B. Softgel formulations of bisphosphonates bone resorption inhibitors
US20050152969A1 (en) 2004-01-08 2005-07-14 Chiprich Timothy B. Colored liquid-filled soft capsules and method of manufacture thereof
US20050175686A1 (en) 2004-02-11 2005-08-11 Ramachandran Radhakrishnan Drug delivery system using a solubilized gelatin shell composition and unit dose drug delivery using a special shape soft gelatin capsule
US20060009425A1 (en) 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
GB2429916A (en) 2004-06-07 2007-03-14 Strides Arcolab Ltd Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
BRPI0616330A2 (pt) 2005-09-26 2011-06-14 Novacea Inc prevenÇço e tratamento de distérbios gastrintestinais e da bexiga associados com quimioterapia ou radioterapia usando compostos ativos com vitamina d
US20070098819A1 (en) * 2005-11-02 2007-05-03 Susan Thys-Jacobs Micronutrient supplement with calcium, vitamin D or calcium & vitamin D combination for premenstrual syndrome, postpartum depression, depression and panic attacks
CA2882048C (fr) * 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
US8501717B2 (en) * 2007-02-09 2013-08-06 Merck, Sharp & Dohme Corp. Methods to treat and/or prevent mucositis
KR101495578B1 (ko) 2007-04-25 2015-02-25 사이토크로마 인코포레이티드 비타민 ｄ 부족 및 결핍의 치료 방법
ES2956794T3 (es) * 2007-04-25 2023-12-28 Eirgen Pharma Ltd Liberación controlada de 25-hidroxivitamina D
US8759328B2 (en) * 2008-07-24 2014-06-24 Wisconsin Alumni Research Foundation Once-a-week administration of 25-hydroxy vitamin D3 to sustain elevated steady-state pharmacokinetic blood concentration
WO2010075065A2 (fr) 2008-12-15 2010-07-01 Banner Pharmacaps, Inc. Procédés pour augmenter la libération et l'absorption d'agents actifs insolubles dans l'eau
WO2010117873A2 (fr) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Solutions de progestérone à plus grande biodisponibilité
WO2012047098A1 (fr) 2010-10-04 2012-04-12 Dishman Pharmaceuticals And Chemicals Ltd. Vitamine liposoluble encapsulée
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3053598A1 (fr) 2015-02-06 2016-08-10 Faes Farma, S.A. Capsules molles de calcifédiol

Also Published As

Publication number Publication date
MX2017006272A (es) 2017-08-14
MD3204047T2 (ro) 2020-06-30
KR101971384B1 (ko) 2019-04-22
ZA201703444B (en) 2019-09-25
EP3204047A1 (fr) 2017-08-16
JP6697779B2 (ja) 2020-05-27
LT3204047T (lt) 2020-07-10
WO2016124724A1 (fr) 2016-08-11
KR20170093123A (ko) 2017-08-14
CL2017001335A1 (es) 2018-01-19
CN106999441B (zh) 2020-11-24
MA41058B1 (fr) 2020-05-29
BR112017010657B1 (pt) 2022-10-11
CN106999441A (zh) 2017-08-01
PL3204047T3 (pl) 2020-08-24
EP3204047B1 (fr) 2020-05-27
EP3689380A1 (fr) 2020-08-05
RS64166B1 (sr) 2023-05-31
CO2017004545A2 (es) 2017-08-31
CN112843014A (zh) 2021-05-28
SI3204047T1 (sl) 2020-07-31
EP3053598A1 (fr) 2016-08-10
ME03739B (fr) 2021-01-20
HRP20200859T1 (hr) 2020-08-21
DK3689380T3 (da) 2023-05-22
BR112017010657A2 (pt) 2018-02-14
JP2018184458A (ja) 2018-11-22
PT3204047T (pt) 2020-06-05
EA034821B1 (ru) 2020-03-25
EP3689380B1 (fr) 2023-03-15
AU2016214336A1 (en) 2017-05-25
JP6427270B2 (ja) 2018-11-21
EA201791097A1 (ru) 2017-08-31
ES2738642T1 (es) 2020-01-24
DK3204047T3 (da) 2020-06-02
KR101971384B9 (ko) 2022-07-25
JP2017536358A (ja) 2017-12-07
CA2967170C (fr) 2018-06-05
ES2738642T3 (es) 2020-11-06
US20170348249A1 (en) 2017-12-07
CY1122976T1 (el) 2021-10-29
US10525018B2 (en) 2020-01-07
PE20170911A1 (es) 2017-07-12
RS60467B1 (sr) 2020-07-31
HUE050133T2 (hu) 2020-11-30
ES2941385T3 (es) 2023-05-22
PH12017501350A1 (en) 2017-12-18
MX367999B (es) 2019-09-12
CA2967170A1 (fr) 2016-08-11
MY189432A (en) 2022-02-11
AU2016214336B2 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
ZA201708561B (en) Microcapsules
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3305788T3 (da) Janus-kinase-hæmmer
DK3277719T3 (da) Polypeptider
MA52507A (fr) Capsules molles de calcifédiol
DK3310450T3 (da) Olie-vand-separator
GB201608157D0 (en) Capsules
DK3283058T3 (da) Ribociclib-tablet
DK3270930T3 (da) Præeklampsi
DK3292136T3 (da) Penicillin-g-acylaser
DK3338804T3 (da) Enterisk kapsel
DK3274482T3 (da) Stenborsknop
DK3318308T3 (da) Badmintonketsjer
DE112015005904A5 (de) Gurtschlossbringer
DE112016005599A5 (de) Strahlungsgrill
DE102015206660A8 (de) Plattenaufteilanlage
EP3329121C0 (fr) Pont
GB201502316D0 (en) Bitcon technology
GB201502073D0 (en) HDEG technology
DE112016001124A5 (de) Spannschutz
DE102015000551A8 (de) Rotationszerstäuberturbine
CL2017001140S1 (es) Cápsula
CL2017001144S1 (es) Cápsula
CL2017001147S1 (es) Cápsula
CL2017001146S1 (es) Cápsula